Threshold Pharmaceuticals Newswire

Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 45 in Threshold Pharmaceuticals

  1. Threshold Pharmaceuticals Inc. (THLD) to Release Earnings on ThursdayRead the original story w/Photo

    Wednesday | AmericanBankingNews.com

    Threshold Pharmaceuticals Inc. is scheduled to issue its quarterly earnings data after the market closes on Thursday, July 28th. Analysts expect the company to announce earnings of per share for the quarter.

    Comment?

  2. Threshold Pharmaceuticals Inc. (THLD) Position Maintained by Cormorant Asset Management LLCRead the original story w/Photo

    Monday Jul 25 | Daily Political

    Cormorant Asset Management LLC maintained its stake in shares of Threshold Pharmaceuticals Inc. during the first quarter, Holdings Channel reports. The institutional investor owned 1,000,000 shares of the biotechnology company's stock at the end of the first quarter.

    Comment?

  3. Threshold Pharmaceuticals Inc. (THLD) Short Interest UpdateRead the original story w/Photo

    Friday Jul 15 | AmericanBankingNews.com

    Threshold Pharmaceuticals Inc. saw a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 477,934 shares, a decrease of 83.5% from the June 15th total of 2,902,050 shares.

    Comment?

  4. BlackRock Fund Advisors Has $741,000 Position in Threshold Pharmaceuticals, Inc.Read the original story w/Photo

    Jun 10, 2016 | Daily Political

    BlackRock Fund Advisors lowered its stake in shares of Threshold Pharmaceuticals, Inc. by 5.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,610,250 shares of the biotechnology company's stock after selling 91,466 shares during the period.

    Comment?

  5. Most Popular Healthcare Penny Stocks Among Hedge FundsRead the original story

    Jun 9, 2016 | Insider Monkey

    ... Inc. (NASDAQ:SNSS) are down more than 35% year-to-date and currently trade at $0.57. Next up is Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), which is down by 1.65% since the beginning of the year, and whose shares trade at $0.47. The FDA said ...

    Comment?

  6. FDA says Threshold's evofosfamide trial data not there to support an NDA filingRead the original story w/Photo

    Jun 6, 2016 | Seeking Alpha

    As expected, the FDA informs Threshold Pharmaceuticals that the results from its Phase 3 clinical trial, EMR200592-001, and its Phase 2 study, TH-CR-404, do not provide adequate efficacy data to support a New Drug Application seeking approval of evofosfamide for the treatment of patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma previously untreated with chemotherapy.

    Comment?

  7. Zacks: Brokerages Anticipate Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) to Post -$0.11 EPSRead the original story w/Photo

    May 26, 2016 | Daily Political

    Wall Street brokerages expect Threshold Pharmaceuticals, Inc. to report earnings per share of for the current fiscal quarter, according to Zacks Investment Research . Two analysts have issued estimates for Threshold Pharmaceuticals' earnings.

    Comment?

  8. What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma,...Read the original story

    May 18, 2016 | Freshnews

    The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. , Seattle Genetics Inc. , Chiasma Inc. , and Ophthotech Corp. .

    Comment?

  9. Threshold Pharmaceuticals, Inc. (THLD) Announces Earnings ResultsRead the original story w/Photo

    May 9, 2016 | Daily Political

    Threshold Pharmaceuticals, Inc. released its earnings results on Thursday. The biotechnology company reported earnings per share for the quarter, missing the Zacks' consensus estimate of by $0.09, Market Beat.com reports.

    Comment?

  10. Threshold Pharmaceuticals, Inc. (THLD) Announces Quarterly Earnings...Read the original story w/Photo

    May 6, 2016 | AmericanBankingNews.com

    Threshold Pharmaceuticals, Inc. posted its earnings results on Thursday. The biotechnology company reported earnings per share for the quarter, missing the Zacks' consensus estimate of by $0.09, Marketbeat reports.

    Comment?

  11. Threshold Pharmaceuticals, Inc. (THLD) to Release Quarterly Earnings on ThursdayRead the original story w/Photo

    Apr 27, 2016 | AmericanBankingNews.com

    Threshold Pharmaceuticals, Inc. will be announcing its earnings results after the market closes on Thursday, April 28th. Analysts expect the company to announce earnings of per share for the quarter.

    Comment?

  12. Week In Review: iCarbonX Closes $155 Million Series A At $1 Billion ValuationRead the original story w/Photo

    Apr 24, 2016 | Seeking Alpha

    The company is the brainchild of Dr. Jun Wang, who previously served as CEO of BGI, China's largest genomic sequencing company. Tencent Holdings , a China internet company, led the financing, and the two companies will establish a strategic relationship.

    Comment?

  13. Penny Stocks List of Top Winners in 2016Read the original story w/Photo

    Apr 19, 2016 | Money Morning

    ... it a perfect addition to our penny stocks list. No. 4 on Our Winning Penny Stocks List for 2016: Threshold Pharmaceuticals Inc. (Nasdaq: THLD) recently reported an incredible fourth-quarter net income gain of $69.7 million. This is after it reported ...

    Comment?

  14. Conquering cancer: Designing a targeted treatmentRead the original story w/Photo

    Apr 6, 2016 | The New Zealand Herald

    ... more than a decade, it is being put throughphase 2 trials in the US and Australia by US company Threshold Pharmaceuticals in patients with certain kinds of lung cancer, head-and-neck cancer or squamous cell skin cancer. Developed by Associate ...

    Comment?

  15. Threshold Pharmaceuticals, Inc. Forecasted to Earn Q1 2016 Earnings ofRead the original story w/Photo

    Mar 18, 2016 | AmericanBankingNews.com

    Threshold Pharmaceuticals, Inc. - Analysts at William Blair raised their Q1 2016 EPS estimates for Threshold Pharmaceuticals in a research report issued to clients and investors on Tuesday, Zacks Investment Research reports. William Blair analyst J. Sonnier now anticipates that the brokerage will post earnings of per share for the quarter, up from their previous forecast of .

    Comment?

  16. Short Interest in Threshold Pharmaceuticals, Inc. (THLD) Increases By 40.8%Read the original story w/Photo

    Jan 31, 2016 | AmericanBankingNews.com

    Threshold Pharmaceuticals, Inc. saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 2,169,360 shares, a growth of 40.8% from the December 31st total of 1,540,359 shares, MarketBeat.com reports.

    Comment?

  17. Threshold Pharmaceuticals gets Nasdaq delisting warningRead the original story w/Photo

    Jan 22, 2016 | Seeking Alpha

    In a filing, Threshold Pharmaceuticals says it's gotten a delisting warning from Nasdaq after 30 straight business days below the $1 minimum bid price. The company will have until July 19 to regain compliance with that rule, by lifting its minimum bid price over $1.00 for 10 straight business days at any time.

    Comment?

  18. Threshold Pharma And Merck KGaA, Darmstadt, Germany Agree To Key...Read the original story

    Jan 11, 2016 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced an update on its evofosfamide program including that Threshold and Merck KGaA, Darmstadt, Germany have agreed upon key terms for the licensing back of all rights to evofosfamide to Threshold. The companies have a global license and co-development agreement for evofosfamide, an investigational hypoxia-activated prodrug for the treatment of cancer, which was discovered and initially developed by Threshold.

    Comment?

  19. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Receives Consensus...Read the original story w/Photo

    Dec 30, 2015 | AmericanBankingNews.com

    Shares of Threshold Pharmaceuticals, Inc. have been given a consensus recommendation of "Buy" by the six ratings firms that are presently covering the stock, MarketBeat.Com reports . Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company.

    Comment?

  20. Bay Area Threshold Pharma Slashes Two Thirds of WorkforceRead the original story

    Dec 20, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that it has initiated a significant reduction in its workforce in order to focus the company's financial resources in the near term on two ongoing Phase 2 proof-of-concept clinical trials of tarloxotinib bromide* , the company's novel epidermal growth factor receptor tyrosine kinase inhibitor licensed from the University of Auckland, New Zealand. Threshold will reduce its workforce by approximately two-thirds, resulting in between 20-25 remaining employees.

    Comment?